Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort

Basit Öğe Kaydı
dc.contributor.authorIdilman, Ramazan
dc.contributor.authorDemir, Mehmet
dc.contributor.authorAladag, Murat
dc.contributor.authorErol, Cihan
dc.contributor.authorCavus, Bilger
dc.contributor.authorIliaz, Raim
dc.contributor.authorKoklu, Hayrettin
dc.contributor.authorCakaloglu, Yilmaz
dc.contributor.authorSahin, Memduh
dc.contributor.authorErsoz, Galip
dc.contributor.authorKoksal, Iftihar
dc.contributor.authorKarasu, Zeki
dc.contributor.authorOzgenel, Meric
dc.contributor.authorTuran, Ilker
dc.contributor.authorGunduz, Feyza
dc.contributor.authorAtaseven, Huseyin
dc.contributor.authorAkdogan, Meral
dc.contributor.authorKiyici, Murat
dc.contributor.authorKoksal, Aydin Seref
dc.contributor.authorAkhan, Sila
dc.contributor.authorGunsar, Fulya
dc.contributor.authorTabak, Fehmi
dc.contributor.authorKaymakoglu, Sabahattin
dc.contributor.authorAkarca, Ulus S.
dc.contributor.authorAkarsu, Mesut
dc.contributor.authorAlkim, Huseyin
dc.contributor.authorAraz, Filiz
dc.contributor.authorAtes, Fehmi
dc.contributor.authorAygen, Bilgehan
dc.contributor.authorBalik, Ismail
dc.contributor.authorBarut, Huseyin S.
dc.contributor.authorBaysal, Birol
dc.contributor.authorBolat, Aylin
dc.contributor.authorCelik, Ilhami
dc.contributor.authorCosgun, Suleyman
dc.contributor.authorEnsaroglu, Fatih
dc.contributor.authorGokcan, Hale
dc.contributor.authorGurel, Selim
dc.contributor.authorGursoy, Sebnem
dc.contributor.authorInkaya, Ahmet Cagan
dc.contributor.authorKamilli, Cemil
dc.contributor.authorKav, Taylan
dc.contributor.authorKuruuzum, Ziya
dc.contributor.authorOnder, Fatih O.
dc.contributor.authorOrmeci, Necati
dc.contributor.authorOzbakir, Omer
dc.contributor.authorOzenirler, Seren
dc.contributor.authorOzer, Birol
dc.contributor.authorOzkan, Hasan
dc.contributor.authorPoturoglu, Sule
dc.contributor.authorSenates, Ebubekir
dc.contributor.authorSimsek, Halis
dc.contributor.authorToka, Bilal
dc.contributor.authorUnal, Hakan
dc.contributor.authorYaras, Serkan
dc.contributor.authorYildirim, Abdullah E.
dc.contributor.authorYildirim, Beytullah
dc.contributor.authorYilmaz, Bulent
dc.contributor.authorYilmaz, Hasan
dc.contributor.authorYozgat, Ahmet
dc.contributor.authorYurdaydin, Cihan
dc.date.accessioned2019-10-27T09:44:02Z
dc.date.available2019-10-27T09:44:02Z
dc.date.issued2019
dc.departmentEge Üniversitesien_US
dc.description.abstractThe aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease and to analyse whether the use of LDV/SOF treatment is associated with a new occurrence of hepatocellular carcinoma (HCC) during and after LDV/SOF treatment. The Turkish Early Access Program provided LDV/SOF treatment to a total of 200 eligible CHC patients with advanced liver disease. The median follow-up period was 22months. All patients were Caucasian, 84% were infected with genotype 1b, and 24% had a liver transplantation before treatment. The sustained virological response (SVR12) was 86.0% with ITT analysis. SVR12 was similar among patients with Child-Pugh classes A, B and C disease and transplant recipients. From baseline to SVR12, serum ALT level and MELD score were significantly improved (P<0.001). LDV/SOF treatment was generally well tolerated. Only one patient developed a new diagnosed HCC. Seventeen of the 35 patients, who had a history of previous HCC, developed HCC recurrence during the LDV/SOF treatment or by a median follow-up of 6months after treatment. HCC recurrence was less commonly observed in patients who received curative treatment for HCC compared with those patients who received noncurative treatment (P=0.007). In conclusion, LDV/SOF with or without ribavirin is an effective and tolerable treatment in CHC patients with advanced liver disease. Eradication is associated with improvements in liver function and a reduced risk of developing a new occurrence of HCC. Ledipasvir and sofosbuvir with or without ribavirin is an effective and tolerable treatment in hepatitis C virus-infected patients with advanced liver disease. Eradication is associated with improvements in liver function and reduces the risk of developing a new occurrence of hepatocellular carcinoma.en_US
dc.identifier.doi10.1111/jvh.13075en_US
dc.identifier.endpage674en_US
dc.identifier.issn1352-0504
dc.identifier.issn1365-2893
dc.identifier.issue6en_US
dc.identifier.pmid30740820en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage666en_US
dc.identifier.urihttps://doi.org/10.1111/jvh.13075
dc.identifier.urihttps://hdl.handle.net/11454/28950
dc.identifier.volume26en_US
dc.identifier.wosWOS:000469027000006en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal of Viral Hepatitisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectcirrhosisen_US
dc.subjectdirect-acting antiviralsen_US
dc.subjecthepatitis C virusen_US
dc.subjecthepatocellular carcinomaen_US
dc.subjectliver transplantationen_US
dc.titleLow recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohorten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu